Feedback / Questions
pivekimab sunirine (IMGN632) - Jazz
Pivekimab sunirine: Patent expiry related to composition-of-matter in 2036
(Immunogen)
-
Nov 16, 2023 -
Corporate Presentation
Patent
•
Oncology
https://investor.immunogen.com/static-files/590a2ec5-4d6f-44fc-98fc-64d1512e8112
Nov 16, 2023
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious